#cannabisheals | Mike Robinson

🧠 While anecdotal claims about cannabis healing properties circulate widely on social media, the underlying neurobiology involving endocannabinoid signaling is legitimate but far more nuanced than public messaging suggests. Endogenous cannabinoids like anandamide and 2-AG do modulate pain, mood, and inflammatory pathways, yet exogenous cannabis administration produces a different pharmacological profile—with variable bioavailability, unpredictable cannabinoid ratios, and individual genetic differences in cannabinoid receptor expression that complicate therapeutic prediction. The evidence base remains limited for most clinical conditions; while some conditions like chemotherapy-induced nausea or certain seizure disorders show promise, many claimed benefits lack robust randomized controlled trials, and we cannot yet reliably predict which patients will benefit or tolerate therapy. Healthcare providers should distinguish between mechanistic plausibility and clinical efficacy when counseling patients, acknowledge the gap between